Rapport officer plans $102K stock sale in 2026
Rapport Therapeutics, Inc. (RAPP) received a Form 144 notice indicating that officer Krishnaswamy Yeleswaram plans to sell up to 2,092 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 08/19/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rapport Therapeutics, Inc. (RAPP) received a Form 144 notice indicating that officer Krishnaswamy Yeleswaram plans to sell up to 2,092 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 08/19/2026.
The shares were acquired upon vesting of restricted stock units between 06/09/2024 and 02/09/2025 and are described as Founders Shares. The filing lists an aggregate market value of about $102,528.92 for the planned sale and reports 47,978,286 shares of common stock outstanding.
Key Figures
Key Terms
Rule 144 regulatory
restricted stock units financial
control securities financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing mean for Rapport Therapeutics (RAPP)?
AI-generated analysis. How Rhea-AI works. Not financial advice.